Project Grant DP2AI176138
Award Date
9/7/22
Completion Date
8/31/25
Dollars Obligated
$2.8M
Funding Federal Agency
Office of the Director
Awarding Federal Agency
National Institute of Allergy and Infectious Diseases
Federal Grant Program
93.310
Assistance Type
Project Grant
Place of Performance
Pennsylvania, USA
Similar Awards
The University of Pittsburgh has been awarded a $681,379 Project Grant from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) to evaluate B-T cell cross talk within tertiary lymphoid structures in melanoma progression and immune checkpoint blockade. The award has a performance period from July 1, 2024 to June 30, 2027. This research project aims to enhance understanding of the immune processes involved in melanoma development and response to...
This $1,271,780 Project Grant award from the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395) supports the development of small molecule adaptors for controlling and enhancing the targeting capabilities of universal chimeric antigen receptor (CAR) T-cell therapy. The key objectives are to: 1) Develop small molecule adaptors for directing universal CAR T-cells to multiple antigens, including tumor cells and immunosuppressive cells, 2) Improve CAR targeting...
This Project Grant award, funded by the National Institute of Biomedical Imaging and Bioengineering (NIBIB) under the Discovery and Applied Research for Technological Innovations to Improve Human Health program (CFDA 93.286), supports research to engineer a three-cell synthetic immunotherapy system combining T cells, natural killer cells, and macrophages. The $207,900 award to The Leland Stanford Junior University aims to develop and screen libraries of chimeric antigen receptors (CARs) and...
This $435,699 National Science Foundation project grant funds research at The Johns Hopkins University to develop multi-specific down-regulating antibodies targeting immune checkpoint proteins. The goal is to discover and design custom antibodies that can induce clustering and down-regulation of checkpoint proteins, eliminating them from the cell surface and mobilizing the immune response against cancer. This innovative trafficking-based mechanism could offer an alternative to currently approved...
The New York University (NYU) School of Medicine was awarded a $1,525,500 Project Grant by the National Institutes of Health (NIH) Office of the Director under the Trans-NIH Research Support program (CFDA 93.310). The grant funding, which runs from September 1, 2024 to August 31, 2027, supports the development of new technologies to address two major bottlenecks in the chimeric antigen receptor (CAR) T cell therapy development process: identifying tumor-specific antigens and engineering...
The University of Pittsburgh received a $679,937 Project Grant from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research) to conduct research on mechanisms and therapeutic targeting of T cell regulation in heart allograft recipient monkeys. The 5-year project aims to investigate the impact of cytokine modulation and administration of novel, donor-specific chimeric antigen receptor regulatory T cells (CARTREG) on promoting long-term...
This $1,383,800 federal Project Grant award from the Department of Health and Human Services' National Institutes of Health, under the Trans-NIH Research Support (CFDA 93.310) program, supports the University of Pittsburgh's research to develop new methods for creating and testing developmental signaling patterns. The project aims to leverage high-throughput optogenetic manipulation to build libraries of paired data on developmental signaling patterns and resulting tissue structures. This...
This Project Grant award, worth $647,861.00, was provided by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) to the University of Pittsburgh. The funding will support a 3-year research project evaluating the interplay between B-cells and T-cells within the tumor microenvironment of melanoma, and the impact on immune checkpoint blockade therapies. The University of Pittsburgh, a major recipient of federal biomedical research grants, will...
This Project Grant award of $176,712 from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) supports research at the University of Pittsburgh to investigate mechanisms of cancer immunosurveillance. The research aims to develop a new mouse model to evaluate the role of the CD91 receptor on antigen presenting cells in priming T cell responses against emerging tumors. Specifically, the project will explore how tumor-derived heat shock proteins delivered through the CD91...
This federal Project Grant award from the National Institute of General Medical Sciences (NIGMS) Biomedical Research and Research Training Program (CFDA 93.859) provides $408,750.00 to develop synthetic oligonucleotide nanostructures that can precisely program interfacial interactions at immune system interfaces. The primary objectives are to: 1) Determine how cargo component spacing modulates receptor interactions and affects downstream immunomodulation; and 2) Elucidate the role of cargo...